emerging glp-1 gip obesity treatments 2025 Q&A: Long-term success of therapies hinges on more than just a prescription What's next for GLP-1 innovation:

Coverage approval hinges on meeting specific BMI criteria with documented health conditions and proving other weight loss methods have failed over several months

Haydon, P

Step 5: Track your response

Our gradual titration minimizes these

For patients thinking through long-term use, tirzepatide long-term use research and how long you can take semaglutide both address what extended treatment looks like beyond the initial cutting phase

Patients eligible to enter the trial were 50 years of age or older and had established, stable, CV, cerebrovascular, peripheral artery disease, CKD or NYHA class II and III heart failure or were 60 years of age or older and had other specified risk factors for CV disease